���发背景与监管地位 — Background and Details

By Editorial Desk · published 2026-01-01 · last reviewed 2026-02-12 · Wiki

The short version of ACTH fragment fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2026-02-12 and is reviewed periodically as new material appears.

研发背景与监管地位

当时的短肽研究普遍关注能否穿越血脑屏障、在低剂量下产生中枢效应，Semax 属于这一路线。鼻内给药是其主要使用方式，俄语文献报道的适应症涵盖缺血性卒中、短暂性脑缺血发作、认知功能减退以及视神经病变。这些研究大多发表在当地期刊上，样本规模与终点设置同西方试验惯例存在差异，国际同行对其临床证据的强度看法不一。

各国监管态度分化明显。俄罗斯按处方药管理，部分东欧国家留有使用记录；欧盟与美国未批准其作为药物上市，市面流通品通常标注为研究用化学品。身份差异意味着标示含量、纯度与无菌性缺少统一核查。体育领域还牵涉反兴奋剂名录，跨境携带则受目的地药品法规约束。

Semax 的储存、稳定性与分析

多数实验室与市售的 Semax 以冻干粉形式提供。冻干粉通常建议保存在 -20 °C 或更低温度下，同时避免光照与反复升温。短期运输有时采用冷藏条件，但长期保存仍以冷冻为主。分包操作应尽量减少开盖次数，以降低吸湿和微生物污染的风险。开封后若未一次用完，建议在干燥环境中密封并尽快放回低温储存。

溶液状态的稳定性明显低于冻干粉。肽类在水溶液中可能经历水解、氧化与聚集，其中甲硫氨酸和天冬酰胺等残基常是敏感位点。Semax 含有甲硫氨酸，因此氧化风险相对突出。工作液一般主张现配现用，或冷藏并在数日内用尽。缓冲液种类、pH 和离子强度都会影响降解速率，而关于最佳条件的公开数据并不统一。

Semax at a glance

Background and Development History

Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.

The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.

Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.

Related pages on this site

• Efficient guide
• Structured toolkit
• Verified report
• Connected archive
• Adaptive briefing
• Quality playbook
• Durable playbook
• Focused workbook

Storage Handling and Analytical Verification

Semax is normally supplied as a lyophilized powder, and that form is the most stable. Suppliers commonly recommend storage at -20 °C in a desiccated container protected from light, with short-term handling at room temperature limited to weighing and transfer. Powder that has absorbed moisture degrades faster, so vials should be warmed to ambient temperature before opening to prevent condensation on the contents. Hygroscopic behavior is typical of short hydrophilic peptides, and humidity control matters more than temperature alone for long-term retention.

Once dissolved, the peptide is considerably less stable than the solid. Aqueous solutions are usually prepared at neutral to slightly acidic pH, filtered, and divided into single-use aliquots before freezing. Repeated freeze-thaw cycles are a common cause of avoidable loss and are best prevented by never refreezing a thawed aliquot. Adsorption to plastic and glass surfaces can lower the measured concentration of dilute solutions, particularly below roughly 0.1 mg/mL. Buffer choice, salt content, and container material all influence how much peptide remains detectable after storage.

Chemical Identity and Research Background

Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.

Development of the compound took place in the Soviet Union during the 1980s, largely through peptide research groups affiliated with the Shemyakin-Ovchinnikov Institute and Moscow State University. Investigators screened fragments of adrenocorticotropic hormone for activity on the central nervous system while attempting to separate cognitive effects from hormonal ones. The shortened sequence was selected because it retained behavioral activity in animal models without stimulating corticosteroid release. Early publications described the molecule as an ACTH(4-10) analog.

Background from the literature

== Xenon-136 == Xenon-136 is an isotope of xenon that undergoes double beta decay to barium-136 with a very long half-life of 2.18×1021 years, approximately 11 orders of magnitude longer than the age of the universe. It is being used in the Enriched Xenon Observatory experiment to search for neutrinoless double beta decay.

== Side effects == The most common side effects include gastrointestinal disorders, such as dyspepsia, decreased appetite, nausea, vomiting, abdominal pain, diarrhea. Over the course of a 52-week double-blind study to detect the efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes, the most common side effects seen were nausea, diarrhea, and vomiting [20]. Some patients may experience serious adverse reactions: acute pancreatitis (symptoms include persistent severe abdominal pain, sometimes radiating to the back and accompanied by vomiting), hypoglycemia, renal impairment (which may sometimes require hemodialysis). The risk of hypoglycemia is increased if the drug is used in combination with sulfonylureas or insulin. Some more serious side effects include:

Nine mobile detachments (Wuyi, Jiangsu; Putian, Fujian; Guangzhou; Foshan, Guangdong; Mengzi, Yunnan; Nanchong, Sichuan); Two Special Operations detachments (Guangzhou(Snow Leopard Commando Unit) and Huzhou, Zhejiang); Three Transportation detachments (Hefei, Anhui; Mianyang, Sichuan; Linzhi, Tibet); One Engineering/Chemical Defense detachment (Fuzhou, Fujian); One Helicopter detachment with 3 Groups The incumbent Commander is Major General Chen Hongwu, while the Political Commissar is Major General Yang Zhenguo.

Sources: en.wikipedia.org

Reference notes

=== Antibacterial spectrum === In vitro studies of nadifloxacin showed potent and broad-spectrum antibacterial activity against aerobic Gram-positive, Gram-negative and anaerobic bacteria, including Cutibacterium acnes and Staphylococcus epidermidis. Nadifloxacinshowed potent antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA), which was similar to potency against methicillin-sensitive Staphylococcus aureus (MSSA). The drug was also active against new quinolone-resistant MRSA. Nadifloxacin does not show cross-resistance with other new fluoroquinolones.

An "official" label was announced on November 8 for notable accounts. Hours after the label began rolling out, Musk tweeted that he "killed" the label. Accounts that had been verified through the previous system were renamed to "legacy verified", with Musk calling the previous system "corrupt and nonsensical" in a tweet, and stating the blue checkmarks on those accounts would be removed "in a few months". Musk claimed that the impersonation issue was resolved by manually reviewing all applications, but The Washington Post tech columnist Geoffrey A. Fowler was able to create an impersonation account of senator Ed Markey, which was promptly verified after subscribing to Twitter Blue and only suspended after Fowler's story was published. On December 12, 2022, Twitter Blue was relaunched again with some changes, including an increased price of $11 for users who sign up through iOS devices to compensate for the 30% cut imposed by Apple. Twitter stated that only Twitter accounts older than 90 days and with a confirmed phone number are able to subscribe and Blue checkmarks are issued once Twitter reviews the account, and any changes to the profile "will result in the loss of the blue checkmark" until Twitter can review the account again.

=== Development === The project started with producer Mace Neufeld, and was intended as a prestige thriller headlined by James Caan but that version stalled due to difficulties with the script. Neufeld later partnered with Moshe Diamant to pitch it, under the title Heart of Stone, to football player and aspiring actor Brian Bosworth. Diamant's Epic Productions had formed a joint venture with Michael Douglas and Rick Bieber's Stonebridge Entertainment called the Stone Group and the Douglas connection was an added incentive to Bosworth. Joining the other executive producers was Gary Wichard, Bosworth's personal manager who had spearheaded his transition to movies. Producer duties were entrusted to Yoram Ben Ami, CEO of Triumph Releasing, a Columbia Pictures subsidiary that usually dealt with Diamant's product. During pre-production, the screenplay was attributed to Walter Doninger and Howard Cushnir (the latter is absent from the final credits). It was retooled for Bosworth, who consulted with the writers over about one year. A late pre-production report claimed that the story was to be set in the Midwest. However, Ben Ami indicated that the Deep South region had been chosen because it was in the script, and some of the eventual locations had been in talks to host since at least summer 1989.

Sources: en.wikipedia.org

Frequently asked questions